An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: A possible new therapeutic option for good responders to the initial induction treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 11, 2013, Pages 1444-1447

  Taniguchi, T ^a   Noda, S ^a   Takahashi, N ^a   Yoshimura, H ^a   Mizuno, K ^a   Adachi, M ^a  

^a KANTO ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB;

ADULT; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INJECTION SITE REACTION; JAPANESE; LOADING DRUG DOSE; MAINTENANCE THERAPY; MALE; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; TREATMENT OUTCOME;

EID: 84885956322     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04610.x     Document Type: Article

References (11)

1. Lebwohl M,. Psoriasis. Lancet 2003; 361: 1197-1204.
2. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
3. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
4. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
5. Noda S, Mizuno K, Adachi M,. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital. J Dermatol 2011; 39: 265-268.
6. Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2011; 66: 241-251.
7. Inzinger M, Heschl B, Weger W, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol 2011; 165: 640-645.
8. Kircik LH, Del Rosso JQ,. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol 2009; 8: 546-559.
9. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
10. Fotiadou C, Lazaridou E, Sotiriou E, et al. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre. J Eur Acad Dermatol Venereol 2011; doi: 10.1111/j.1468-3083.2011.04290.x. [Epub ahead of print].
11. Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-132.